Cardiotoxicity of cytotoxic chemotherapy and its prevention

Adverse Drug Reactions and Toxicological Reviews

Volumn 18, Issue 2, 1999, Pages 61-105

  Selvaratnam, G ^a   Philips, R H ^b   Mohamed, Ahmad Kamal ^c  

^a Jalan BBN 12/1   (Malaysia)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c HOSPITAL KUALA LUMPUR   (Malaysia)

Author keywords

Amelioration of cardiotoxicity; Amifostine; Anthracyclines; Arrhythmias; Bone marrow transplant; Cardiac imaging; Cardiotoxicity; Chemotherapy in children; Dexrazoxane; Heart failure; Side effects of chemotherapy

Indexed keywords

AMIFOSTINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CALCIUM ION; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; MITOXANTRONE; MONOCLONAL ANTIBODY; PACLITAXEL; PHOSPHOLIPID; RAZOXANE;

BONE MARROW TRANSPLANTATION; CALCIUM TRANSPORT; CARDIOTOXICITY; EARLY DIAGNOSIS; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE BIOPSY; HEART PROTECTION; HISTOPATHOLOGY; REVIEW; RISK FACTOR; SCINTIANGIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART DISEASES; HUMANS; MALE; RISK FACTORS;

EID: 0032772662     PISSN: 0964198X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (340)

1. Goorin AM, Borow KM, Goldman A, Williams RG, Henderson IC, Sallan SE, et al. Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer 1981; 47: 2810-16.
2. Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M, et al. Doxorubicin-induced congestive heart failure in adults. Cancer 1985; 56: 1361-5.
3. Ali MK, Ewer MS, Gibbs HR, et al. Late doxorubicin-associated cardiotoxicity in children. Cancer 1994 July 1; 74 (1): 182-8.
4. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63: 827-34.
5. Bristow MR, Thomson PD, Martin RP, et al. Early anthracycline cardiotoxicity. Am J Med 1978; 65: 823-32.
6. Brenner DE, Wiernik PH, Wesley M, Bachur NR. Acute Doxorubicin toxicity. Cancer 1984; 53: 1042-8.
7. Antibiotics: doxorubicin HCl. In: Cada DJ (ed). Drug Facts and Comparisons. 48th ed. St. Louis: Facts & Comparisons, Inc. 1994: 2703-5.
8. Schwartz C, Hobbie W, Truesdell S, Constine L, et al. Corrected QT interval prolongation in anthracycline treated survivors of childhood cancer. J Clin Oncol 1993; 11: 1906-10.
9. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981; 305: 159-63.
10. Billingham ME, Mason JW, Bristow MR, et al. Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Rep 1978; 62: 865-72.
11. Blum RH, Carter SK. Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med 1974; 80: 249-59.
12. Mushlin PS, Olson RD. Anthracycline cardiotoxicity. New Insights. Rational Drug Ther 1988; 12: 1-8.
13. Moreg, Oylon DJ. Outcomes of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer 1992; 70: 2637-41.
14. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979; 91: 710-17.
15. Lipp HP. Prevention and management of anti-cancer drug toxicity. Universitatsverlag Jena 1995: 62-72.
16. Brade WP, Herdrich K, Varini M. Ifosphamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12: 1-47.
17. Dresdale AM, Bonow RO, Wesley R, et al. Prospective evaluation of doxorubicin induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 1983; 52: 51-60.
18. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing Anthracycline therapy. JAMA 1991; 226: 1672-7.
19. Weiss RB. The Anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 19: 670-86.
20. Lefrak EA, Pitha J, Rosehelm S, et al. A clinical pathologic analysis of Adriamycin cardiotoxicity. Cancer 1973; 32: 302-14.
21. Lenaz LN, Page JA. Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat Rev 1976; 3: 111-20.
22. Dobric S, Dragojevic-Simic V, Bokonjic D, et al. The efficiency of Selenium, WR2721, and their combination in the prevention of doxorubicin induced cardiotoxicity in rats. J Environ Pathol Toxicol Oncol 1998; 17(3-4): 291-9.
23. Dorr RT. Cytoprotective Agents for Anthracyclines. Semin Oncol 1996; Aug. 23 (4Suppl8): 23-24.
24. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues for selective protection of normal tissues by S-(2-3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1980; 40: 1519-24.
25. Calabro-Jones PM, Aguilera JA, Ward JF, et al. Uptake of WR2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res 1988; 48: 3634-40.
26. Balcerzak SP, Christakis J, Lewis RP, et al. Systolic time intervals in monitoring Adriamycin-induced cardiotoxicity. Cancer Treat Rep 1979; 62: 827-34.
27. Benjamin RS, Ewer MS, Macky B, et al. An endomyocardial biopsy study of anthracycline-induced cardiomyopathy, detection, reversibility, and potential amelioration. Proc Am Soc Clin Oncol 1979; 20: C-335,372.
28. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-15.
29. Steinherz LJ, Steinherz PG, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-7.
30. Lipschultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-43.
31. Goorin AM, Chauvenet AR, Perez-Atayde AR, et al. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990; 116: 144-7.
32. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-15.
33. Leandro J, Dyke J, Poppe D, et al. Cardiac dysfunction late after cardio-toxic therapy for childhood cancer. Am J Cardiol 1994; Dec 74: 1152-6.
34. Cuthberson DD, Epstein ST, Lipshultz SE, et al. Anthracycline cardiotoxicity in children with cancer. Circulation 1994; 90: 1-50.
35. Calabro-Jones PM, Fahey RC, Smoluk GD, et al. Alkaline phosphatase promotes radioprotection and accumalation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 1985; 47: 23-7.
36. Lipshultz S, Lipsitz S, Mone S, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-43.
37. Romanul FCA, Bannister RG. Histochemistry: Localized areas of high alkaline phosphatase activity in endothelium of arteries. Nature 1962; 195: 611-12.
38. Paplanus SH, Zbar MJ, Hays JW. Cardiac hypertrophy as a mainifestation of chronic anemia. Am J Pathol 1958; 34: 149.
39. Woodruff JF. The influence of quantitated post-wearing under nutrition on Coxsackievirus B-3 infection of adult mice: II: alteration of host defense mechanisms. J Infect Dis 1970; 121: 164-8.
40. Porembka DT, Lowder JN, Orlowski JP, et al. Etiology and management of doxorubicin cardiotoxicity. Crit Care Med 1989; 17: 69-72.
41. List AF, Heaton R, Glinsmann-Gibson B, et al. Amifostine protects primitive human haematopoetic progenitors against cytotoxicity from diverse antineoplastics. Proc Am Soc Clin Oncol 1996; 15: 448.
42. Dorr RT, Lagel KE. Anthracycline cardioprotection by amifostine (WR-2721) and its active metabolite (WR-1065) in vitro. Proc Am Soc Clin Oncol 1994; 13: 435.
43. Green D, Wright A, Schein PS, et al. WR-2721 chemoprotection of doxorubicin toxicity in mice. Proc Am Assoc Cancer Res 1992; 33: 490.
44. Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardiac protection during chemotherapy. Curr Opin Oncol 1995; 7: 304-9.
45. Valagussa P, Zambetti M, Biasi S, Moliterni A, et al. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 1994; 5: 209-16.
46. Yuhas JM. A more general role for WR-2721 in Cancer Therapy. Br J Cancer 1980; 41: 832-4.
47. Yuhas JM, Spellman JM, Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 1980; 3: 211-16.
48. Krischer J, Epstein S, Cuthberson D, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer. The Pediatric Oncology Group experience. J Clin Oncol 1997; 15: 1544-52.
49. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, et al. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes in its biotransformation. Cancer Res 1994; 54: 386-92.
50. Speyer J, Freedberg R. Cardiac complication. In: Abeloff M, Arminage J, Lichter A, et al. Clinical Oncology. New York, NY: Churchill Livingstone 1995: 809-19.
51. Legha SS, Benjamin RS, Mackat B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-9.
52. Holmberg SRM, Williams AJ. Patterns of interaction between anthraquinone drugs and the adriamycin release channel from cardiac sarcoplasmic reticulum. Cric Res 1990; 67: 272-83.
53. 2+ release channel from rat cardiac sarcoplasmic reticulum: possible receptor mediated mechanism of doxorubicin cardiomyopathy. Mol Pharmacol 1990; 37: 503-14.
54. Myers C. Role of iron in anthracycline action. In: Hacker M, Lazo J, Tritton T (eds). Organ Directed Toxicities of Anticancer Drugs. Boston, MA, Martinus Nijhoff 1988; 17-31.
55. Myers C, Gianni L, Simone C, et al. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin iron complex. Biochemistry 1982; 21: 1713-19.
56. Doroshow J. Role of reactive oxygen production in doxorubicin cardiac toxicity. In: Hacker M, Lazo J, Tritton T (eds). Organ Directed Toxicities of Anticancer Drugs. Boston, MA, Martinus Nijhoff 1988; 31-40.
57. Muggia F, Hainsworth J, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-93.
58. Olakanmi O, McGowan SE, Hayek MB, Britigan BE. Iron sequestration by macrophages decreases the potential of extracellular hydroxyl radical formation. J Clin Invest 1993; 91: 889-99.
59. Weiss G, Kastner S, Brock J, Thaler J, et al. Modulation of transferrin receptor expression by dexrazoxane via activation of iron regulatory protein. Biochem Pharmacol 1997 May 15; 53(10): 1419-24.
60. Doroshow JH. Doxorubicin induced cardiac toxicity. N Engl J Med 1991; 324: 843-5.
61. Doroshow JH, Akman S, Chu F-F, et al. Role of the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer quinones. Pharmacol Ther 1990; 47: 359-70.
62. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990; 4: 3076-86.
63. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolities: alterations produced by doxorubicin. J Clin Invest 1980; 65: 128-35.
64. Mimnaugh EG, Gram TE, Trush MA. Stimulation of mouse heart and liver microsomal lipid peroxidation by anthracycline drugs: characterization and effects of reactive oxygen scavengers. J Pharmacol Exp Ther 1983; 226: 806-16.
65. Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 1978; 38: 1745-50.
66. Yuhas JM. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 1979; 63: 971-6.
67. Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity of Cis-dichlorodiamine-platinum by WR-2721 without altering its antitumour properties. Cancer Treat Rep 1980; 64: 57-64.
68. Davidson DE, Grenan MM, Sweeney TR. Biological characteristics of some improved radioprotectors. In: Brady L (ed). Radiation Sensitisers, New York, NY, Mason 1980; 309-20.
69. Lown JW, Chen H, Plambeck JA. Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects. Biochem Pharmacol 1982; 31: 575-81.
70. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumour response. Science 1977; 197: 165-7.
71. Goormaghtigh E, Chatelain P, Caspers J, et al. Evidence of a complex between Adriamycin derivatives and cardiolipin: Possible role in cardiotoxicity. Biochem Pharmacol 1980; 29: 3003-10.
72. Gianni L, Zweier L, Levy A, et al. Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen. J Biol Chem 1985; 197: 165-7.
73. Gianni L, Vigano L, Lanzi C, et al. Role of daunosamine and hydroxyl acetyl side chain in reaction with iron and lipid peroxidation. J Natl Cancer Inst 1980; 80: 1104-11.
74. Muindi JR, Sinha BK, Gianni L, et al. Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. FEBS Lett 1984; 172: 226-30.
75. Muindi JR, Sinha BK, Gianni L, et al. Thiol-dependent DNA damage produced by anthracyclineiron complex: the structure activity relationships and molecular mechanisms. Mol Pharmacol 1985; 27: 356-65.
76. Bajamonde A, Fleming T, Eirmann W, et al. Addition of Herceptin to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized multinational controlled phase 3 trial. Proc Am Soc Clin Oncol (ASCO) 1998; 16: 377.
77. 3+-ADP-EDTA systems. Biochim Biophys Acta 1983; 753: 411-21.
78. 2 reduction by the iron complexes of adriamycin and daunomycin: the importance of side chain hydroxyl group. Biochem Biophys Acta 1986; 884: 326-836.
79. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin as a single agent in 222 women with HER2 over expression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol (ASCO) 1998; 16: 376.
80. Rhoden W, Haselton P, Brooks N. Anthracyclines and the heart. Br Heart J 1993; 70: 499-502.
81. Weiss RB, Grillo-Lopez AJ, Marsoni S, et al. Amsacrine associated cardiotoxicity: An analysis of 82 cases. J Clin Oncol 1986; 4: 918-28.
82. Julicher RH, Sterrenberg L, Bast A, et al. The role of lipid peroxidation in acute doxorubicin cardiotoxicity as studied in rat isolated heart. J Pharm Pharmacol 1985; 38: 277-82.
83. Cortes-Funes H, Martin C, Abratt R, et al. Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer. Anti-Cancer Drugs 1997; 8(6): 582-7.
84. Goodman J, Hochestein P. Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem Biophys Res Com 1977; 77: 797-803.
85. Jackson JA, Reeves JP, Muntz KH, Kruk D et al. Evaluation of free radicals effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol 1984; 117: 140-53.
86. Paraidathu T, Combs AB, Kehrer JP. In vivo effects of 1,3 bis(2-chloroethyl)-1-nitrosurea and doxorubicin on the cardiac and hepatic glutathione systems. Toxicology 1985; 35: 113-24.
87. Demant EFJ, Wassermann K. Doxorubicin induces alterations in lipid metabolism of cultured myocardial cells. Biochem Pharmacol 1985; 34: 1741-6.
88. Porta EA, Joun NS, Matsumara L, Nakasone B, et al. Acute adriamycin cardiotoxicity in rats. Res Commun Chem Pathol Pharmacol 1983; 41: 125-37.
89. Rajagopalan S, Politi PM, Sinha K, Myers CE, et al. Adriamycin induced free radical formation in the perfused rat heart; implications of cardiotoxicity. Cancer Res 1988; 48: 4766-9.
90. Unverferth DV, Leier CV, Balcerzak SP, Hamlin RL. Usefulness of a free radical scavenger in prenventing doxorubicin induced heart failure in dogs. Am J Cardiol 1985; 56: 157-61.
91. Adis Drug Evaluation. Drugs 1997 54(3): 447-72.
92. Van Fleet JF, Ferrans VJ, Weirich WE. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of Vitamin E and selenium as cardioprotectants. Am J Pathol 1980; 99: 13-42.
93. Herman EH, Ferrans VJ, Myers CE, Van Fleet JF, et al. Comparison of the effectiveness of ICRF-187 and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res 1985; 45: 276-81.
94. Myers C, Bonos R, Palmeri S, Jenkins J, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983; 10: 53-5.
95. Basser RL, Green MD. Complications of treatment: strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 1993; 19: 57-77.
96. Doroshow JH, Locker GY, Ifrim I, et al. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest 1981; 68: 1053-64.
97. Aapro MS, Martin C, Hatty S. Gemcitabine - a safety review. Anti-Cancer Drugs 1998; 9: 191-201.
98. Eli Lilly & Co. Gemzar (gemcitabine HCl): treatment IND program for patients with pancreatic cancer protocol. Indianapolis: Eli Lilly, December 1994.
99. Cusack BJ, Mushlin PS, Voulelis LD, Li X, Boucek RJ, Oison RD. Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol. Toxicol Appl Pharmacol 1993, 118, 177-85.
100. Olson RD, Mushlin PS, Brenner DE, Fleisher S, Cusack BJ, Chang BK, Boucek RJ Jr. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci 1988; 85: 3585-9.
101. Del Tacca M, Danesi R, Ducci M, Bernardini C, Romanini A. Might adriamycinol contribute to adriamycin-induced toxicity? Pharmacol Res Com 1985; 17; 1073-84.
102. Peters JJH, Gordon GR, Kashiwase D, Acton EM. Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin. Cancer Chemother Pharmocol 1981; 7: 65-70.
103. Peters JJH, Gordon GR, Kashiwase D, et al. Tissue distribution of doxorubicin and doxorubicinol on the cardiac and hepatic glutathione systems. Toxicology 1985; 35: 113-24.
104. Pouna PS, Bonoron-Adele, Gourverneur G, Tariosse L, Besse P, Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 1996; 117: 1593-9.
105. Mushlin PS, Cusack BJ, Boucke RJJ, et al. Time related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 1993; 110: 975-82.
106. Li X, Cusack BJ, Boucek RJJ, Mushlin PS, Bledsoe TB, Brenner DE, Olson RD. Effects of daunorubicin and its primary metabolite, daunorubicinol, on cardiac contractility and calcium loading of sarcoplasmic reticulum. FASEB J 1991; 5A: 1395 (Abstract).
107. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990; 4: 3076-86.
108. Mushlin PS, Boucek RJ, Brenner DE, et al. Doxorubicinol: the culprit in doxorubicin cardiotoxicity. Fed Proc (Abstract) 1986; 45: 195.
109. Olson RD, Brebber DE, Mushlin PS, et al. Doxorubicinol: a more potent cardiotoxin than doxorubicin. Proc Am Assoc Cancer Res 1985; 26: 227-31.
110. Boucek RJ, Olson RD, Brenner DE, et al. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. J Biol Chem 1987; 262: 15851-6.
111. Moore, L, Landon EJ, Cooney DA. Inhibition of the cardiac mitochondrial calcium pump by adriamycin. Biochem Med 1977; 18: 131-7.
112. Unverferth DV, Magorien RD, Leier CV, et al. Doxorubicin cardiotoxicity. Cancer Treat Rev 1982; 9: 149-64.
113. Eli Lilly & Co. Gemcitabine HCl (LY188011 HCl): clinical investigation brochure. Indianapolis: Eli Lilly, October 1993.
114. Mandel EM, Lewinsky U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer 1975; 36: 1561-2.
115. Flested RL, Bachur NR. Human liver daunorubicin reductases: In: Weiner H, Wermuth B, Liss AR (eds). Enzymology of Carbonyl Metabolism. New York 1982: 291-305.
116. Ohara H, Miyabe Y, Deyashiki Y, Matsuura K, Hara A. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 1995; 50: 221-7.
117. White DA, Schwartzberg LS, Kris MG, et al. Acute chest pain during Bleomycin infusions. Cancer 1987; 59: 1582-5.
118. Felsted L, Gee M, Bachur NR. Rat liver daunorubicin reductase, and aldo-keto reductase. J Biol Chem 1974; 249: 3672-9.
119. Mitotic inhibitors vinblastine sulphate. In: Cada DJ (ed). Drugs Facts & Comparisons. 48th ed. St Louis: Facts & Comparisons, Inc., 1994: 2729-32.
120. Alexander J, Dainiak N, Berger H, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979; 300: 278-83.
121. Rabkin SW, Otten M, Polimeni PI. Increased mortality with cardiotoxic doses of adriamycin after verapamil pretreatment despite prevention of myocardial calcium accumulation. Can J Physiol Pharmacol 1983; 61: 1050-6.
122. Rabkin SW. Interaction of external calcium concentration and verapamil on the effects of doxorubicin (Adriamycin) in the isolated heart preparation. J Cardiovasc Pharmacol 1983; 5: 848-55.
123. Rabkin SW, Godin DV. Adriamycin cardiotoxicity and calcium entry blockers: the need for caution in the combination. Can J Cardiol 1985; 1: 4-7.
124. Billingham M, Mason J, Bristow M, et al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865-72.
125. Errans V, Sanchez J, Herman E. Pathologic anatomy of animal models of the cardiotoxicity of anthracycline. In: Muggia F, Green M, Speyer J (eds). Cancer Treatment and the Heart. Baltimore, MD, Johns Hopkins University 1992: 89-113.
126. Doroshov JH, Tallent C, Schechter JE. Ultrastructural features of Adriamycin induced skeletal and cardiac muscle toxicity. Am J Pathol 1985; 118: 288-97.
127. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiac toxicity. Can Treat Rep 1978; 62: 955-61.
128. Ferrans V, Sanchez J, Herman E. The role of myocardial biopsy in the diagnosis anthracycline toxicity. In: Muggia F, Breen M, Speyer (eds). Cancer treatment and the Heart. Baltimore, MD, Johns Hopkins University. 1992; pp 198-216.
129. Druck MN, Gulenchyn KY, Evans WK, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer 1984; 53: 1667-74.
130. McKillop JH, Bristow MR, Goris ML, et al. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983; 106: 1048-56.
131. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiac toxicity in childhood lymphoblastic leukemia. J Clin Oncol 1998; 16: 545-50.
132. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity. Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989; 118: 92-8.
133. Sroddard M, Seeger J, Liddell N, et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin induced systolic dysfunction in humans. J Am Coll Cardiol 1992; 20: 62-9.
134. Sonnenblick M, Rosin A. Cardiotoxicity of interferon : a review of 44 cases. Chest 1991; 99: 557-61.
135. Marchandise B, Schroeder E, Bosley A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989; 118: 92-8.
136. Edwards GS. Long term treatment with cis-dichlorodiamine-platinum-vinblastine-bleomycin: possible association with severe coronary artery disease. Cancer Treat Rep 1979; 63: 551-2.
137. Alexander J, Speyer J. Cancer chemotherapy and cardiotoxicity. In: Philips NC, Hamilton C (eds). PA: Meniscus Health Care Communications, 1996.
138. Quesada JR, Talpaz M, Rios A, et al. Clinical Toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 5: 234-543.
139. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven year experience using radionuclide angiocardiography. Am J Med 1987; 82: 1109-18.
140. Lopez M, Vici P, Lauro LD, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998; 16: 1-7.
141. Bhattacharya S, Lahiri A. Clinical role of indium-111 antimyosin imaging. Eur J Nucl Med 1991; 18: 889-95.
142. Yamada T, Matsumori A, Tamaki N, et al. Detection of adriamycin cardiotoxicity with indium-111 labelled antimyosin monoclonal antibody imaging. Jpn Circ J 1991; 55: 377-83.
143. Carrio I, Estorch M, Berna L, et al. Assessment of anthracycline induced myocardial damage by quantitative indium-111 myosin specific monoclonal antibody studies. Eur J Nucl Med 1991; 18: 806-12.
144. Carrio I, Lopez-Pousa A, Estorch M, et al. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111 antimyosin monoclonal antibody studies. J Nucl Med 1993; 34: 1503-7.
145. Hiroe M, Ohta Y, Fujita N, et al. Myocardial uptake of 111 - In monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats. Circulation 1992; 86: 1965-72.
146. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon related cardiomyopathy. Am J Med 1988; 85: 549-51.
147. Martino S, Ratanatharathorn V, Karanes C, et al. Reversible arrhythmias observed in patients treated with recombinant alpha 2 interferon. J Cancer Res Clin Oncol 1987; 113: 376-8.
148. Bristow MR, Lopez MB, Masom JW, Billingham M, et al. Doxorubicin cardiomyopathy: evaluation of phonocardiography, endomyocardial biopsy and cardiac catheterisation. Ann Intern Med 1978; 88: 168-75.
149. Monti E, Piccini F, Villani F, et al. Myocardial contractility and heart pharmacokinetics of adriamycin following a single administration in rats. Cancer Chemother Pharmacol 1986; 18: 289-91.
150. Speyer J, Wasserheit C. Strategies for reducing cardiac toxicity. Semin Oncol 1998 Oct; 25(5): 525-37.
151. Hamm C, Goldmann B, Heeschan C, et al. Emergency room triage of patient with acute chest pain by means of rapid testing for cardiac troponin T or troponin L. N Engl J Med 1997; 337: 1648-53.
152. Herman E, Lipshultz S, Rifai N, et al. Use of cardiac troponin T levels as an indicator of doxorubicin induced cardiotoxicity. Cancer Res 1988; 58: 195-7.
153. Lipshultz S. Ottlinger M, Lipsitz S, et al. Predictive value of serum cardiac troponin T (cTnT) in pediatric patients at risk for myocardial injury. J Am Coll Cardiol 1997; 29: 429A.
154. Bauch M, Ester A, Kimura B, et al. Atrial natriuretic peptide as a marker for doxorubicin induced cardiotoxic effects. Cancer 1992; 69: 1492-7.
155. Piwnica-Worms D, Chiu ML, Kronauge JF. Detection of adriamycin induced cardiotoxicity in cultured heart cells with technetium 99m-SESTAMIBI. Cancer Chemother Pharmacol 1993; 32: 385-91.
156. Kirkwood JM, Ernstoff MS, Davis CS, et al. Comparison of intramuscular and intravenous recombinant alpha 2 interferon in melanoma and other cancers. Ann Intern Med 1985; 103: 32-6.
157. Graf H de, Dolsma WV, Willense PHB, et al. Cardiotoxicity and intensive chemotherapy. Br J Cancer 1997; 76(7): 943-5.
158. Goltlieb JA, Lefrale EA, O'Bryan RM, et al. Total Adriamycin cardiotoxicity: Prevention by dose limitation (abstr). Proc Am Assoc Cancer Res 1973; 14: 88.
159. Bristow MR, Lopez MB, Mason JW, et al. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 1982; 50: 32.
160. Oldham RR. Toxic effects of interferon. Science 1982; 219: 902.
161. Weiss AJ, Metter GE, Fletcher WS, et al. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976; 60: 813-22.
162. Kragel AH, Travis WD, Feinberg L, et al. Pathologic finding associated with interleukin-2 based immunotherapy for cancer: a postmortem study for 19 patients. Hum Pathol 1990; 21: 493-502.
163. Nora R, Abrams JS, Tait NS, et al. Myocardial toxic effects during recombinant interleukin 2 therapy. J Natl Cancer Inst 1989; 81: 59-63.
164. Torri F, Bristow M, Howes A, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: Assessment by endomyocardial biopsy. Ann Intern Med 1983; 99: 745-9.
165. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43: 460-72.
166. Cortes EP, Gupta M, Chou C, et al. CoQ10 and the prevention of adriamycin cardio-toxicity. Am Soc Clin Oncol 1978; 19: 341.
167. Shapira J, Goffried M, Lishner M, et al. Reduced cardiotoxicity of doxorubicin by a six hour infusion regimen. Cancer 1990; 65: 870-3.
168. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiotoxicity of doxorubicin administered by continuous intravenous infusion in combination with chemotherapy for metastatic breast carcinoma. Cancer 1989; 63: 37-45.
169. Benjamin R, Chawla S, Ewer M. Adriamycin cardiotoxicity An assessment of approaches to cardiac monitoring and cardioprotection In: Hacker M, Lazo J, Tritton T (eds). Organ Directed Toxicities of Anticancer Therapy. Boston, MA, Martinus Nijhoff, 1987: 41-55.
170. Miscellaneous antineoplastics, Aldesleukin (interleukin-2). In: Cada DJ (ed). Drugs Facts & Comparisons 48th ed. St. Louis: Facts & Comparisons, Inc., 1994: 2772-9.
171. Von Hoff D, Rozencweig M, Layard M, et al. Daunomycin induced cardiotoxicity in children and adults. The results of 110 cases. Am J Med 1977; 62: 200-8.
172. Bosslet K, Czech J, Hoffman D. Tumour selective prodrug activation by fusion protein mediated catalysis. Cancer Research 1994; 54: 2151-9.
173. Bosslet K, Czech J, Hoffman D. A novel one step tumour selective prodrug activation system. Tumour Targeting 1995; 1: 45-50.
174. Fishman WH, Anlyan AG. The presence of high B glucorinidase activity in cancer tissue. J Biol Chem 1947; 169: 449-50.
175. Young CW, Yagoda A, Bittar ES, Smith SW, et al. Therapeutic trial of aniline mustard in patients with advanced cancer: comparison of therapeutic response with cytochemical assessment of tumour cell B glucorinidase activity. Cancer 1976; 38: 1887-95.
176. Murdter TE, Sperker B, Kivisto KT, McClellan M, et al. Enhanced uptake of doxorubicin into bronchial carcinoma: β-Glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumour site. Cancer Res 1997 June 15; 57: 2440-5.
177. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long circulating liposomes. Cancer Res 1992; 52: 891-6.
178. Gabizon A, Amselem S, Goren D. et al. Preclinical and clinical experience with a doxorubicin-liposome preparation. J Liposome Res 1990; 1: 491-502.
179. Cowens JW, Greco W, Ginsberg R. Pharmacokinetics of doxorubicin encapsulated in liposomes in patients with advanced cancer (Abstract). Proc Am Soc Clin Oncol 1990; 8: 87.
180. Allen TM, Hansen T, Martin F, et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half lives in vivo. Biochem Biophys Acta 1991; 1066: 29-36.
181. Vaage J, Barbera GE, Abra R, et al. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994; 73: 1478-84.
182. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin 2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guide lines. J Clin Oncol 1989; 7: 486-98.
183. Schecter D, Nagler A. Recombinant interleukin 2 and recombinant interferon immunotherapy cardiovascular toxicity. Am Heart J 1992; 123: 1736-9.
184. Berry G, Billingham M, Alderman E, et al. Reduced cardiotoxicity of Doxil in AIDS Kaposi's sarcoma patients compared to a matched control group of cancer patients given doxorubicin. Proc Am Soc Clin Oncol 1996; 15: A843.
185. Panseca G, Valero V, Buzdar A, et al. Decreased cardiotoxicity by TLC D-99 in the treatment of metastatic breast carcinoma. Proc Am Soc Clin Oncol 1995; 14: A99.
186. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the medical outcomes study. Preliminary validation in persons with early HIV. Med Care 1991; 29: 786-98.
187. Presant CA, Scolaro CA, Kennedy M, et al. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993; 341: 1242-3.
188. Forssen EA, Ross ME. DaunoXome treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 1994; 4: 481-512.
189. Berry G, Billingham M, Alderman E, et al. Reduced cardiac toxicity of DOXIL in AIDS Kaposi's sarcoma patients compared to a matched control group of cancer patients given doxorubicin. Proc Am Soc Clin Oncol 1996; 15: A843.
190. Ponseca G, Valero V, Buzdar A, et al. Decreased cardiac toxicity by TLC D-99 in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1995; 14-A99.
191. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 or high dose interleukin 2 alone. N Engl J Med 1987; 316: 889-97.
192. Rhoden W, Hasleton P, Brooks N. Anthracyclines and the heart. Br Heart J 1993; 70: 499-502.
193. Jain KK, Casoer ES, Geller NL, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985; 3: 818-26.
194. Cersosimo R. Idarubicin: an anthracycline antineoplastic agent. Clin Pharm 1992; 11: 152-67.
195. Pouna P, Bonovan-Adele S, Gouverneur G, et al. Anthracycline cardiotoxicity. Br J Pharmacol 1996; 117: 1593-7.
196. Temma K, Akera T, Chugun A, et al. Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart. Eur J Pharmacol 1993; 234: 173-81.
197. Pouna P, Bonoron-Adele S, Gouverneur G, et al. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin. Cancer Chemother Pharmacol 1995; 35: 257-61.
198. Jaenke RS, Deprez-Decampeneere D, Troute A. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. Cancer Res 1980; 40: 3530-6.
199. Gilladoga AC, Manuel C, Tan CT, et al. The cardiotoxicity of adriamycin and daunomycin in children. Cancer 1976; 7: 1070-8.
200. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity, and toxicity. Cancer Treat Rev 1993; 19: 197-228.
201. Du Bois JS, Udelson JE, Atkins MB. Severe reversible global and regional ventricular dysfunction associated with high-dose interleukin-2 immunotherapy. J Immunol 1995; 18: 119-23.
202. Bertazzoli C, Rovero C, Ballerini L, et al. Experimental systemic toxicology of 4′ epidoxorubicin, a new less cardiotoxic anthracycline antitumour agent. Toxicol Appl Pharmacol 1985; 79: 412-22.
203. Polsker GL, Faulds D. Epirubicin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cancer chemotherapy. Drugs 1993; 45(5): 788-856.
204. Decorti G, Klugmann FB, Candussio L. Characterization of histamine secretion induced by anthracyclines in rat peritoneal mast cells. Biochem Pharmacol 1986; 35: 1939-41.
205. Berger DP, Winterhalter BR, Schick U, Hoffken K. Idarubicin - intravenous and oral. Onkologe 1995; 1: 154-66.
206. Martoni A, Piana E, Guaraldi M, et al. Comparative phase II study of idarubicin versus Doxorubicin in advanced breast cancer oncology. Oncology 1990; 47, 427-32.
207. Lopez M, Contegiacomo A, Vici P, et al. A prospective randomized trial of Doxorubicin versus Idarubicin in the treatment of advanced breast cancer. Cancer 1989; 64; 2431-6.
208. Penco S, Casazza AM, Franchi G, et al. Synthesis, antitumor activity, and cardiac toxicity of new 4′ demethoxy-anthracyclines. Cancer Treat Rev 1983; 67: 665-73.
209. Massimo L, Contegiacomo A, Vici P, et al. A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer 1989; 64; 2431-6.
210. Lopez M, Carpano VP, Palpaldo P, et al. Randomized trial of doxorubicin versus oral idarubicin in advanced breast carcinoma. In: Berkarda B, et al. (eds). Progress in Antimicrobial and Anticancer Chemotherapy. Istanbul: Ecomed, 1987: 435-7.
211. Antibiotics, Idarubicin HCl. In: Cada DJ (ed). Drugs Facts & Comparisons. 48th ed. St. Louis: Facts & Comparisons, Inc., 1994: 2698-702.
212. Rasmussen IMN, Schou HS, Hermansen K. Cardiotoxic effects and the influence on the B-adrenoceptor function of doxorubicin (Adriamycin) in the rat. Pharmacol Toxicol 1989; 65: 69-72.
213. Oza M, et al. Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. Ann Oncol 1994; 5: 343-7.
214. Ozyilkan O, Kars A, Guler N, et al. Intrapleural and intraperitoneal palliative treatment of malignant effusions with mitoxantrone (letter, comment). Anticancer Drugs 1993; 4(1): 98-9.
215. Markman H, Hakes T, Reichman B, et al. Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment. Gynecol Oncol 1993; 49: 185-9.
216. Van Mouwerik TJ, Caines P, Ballentine R. Amsacrine evaluation. Drug Intel Clin Pharm 1987; 21: 330-4.
217. Benjamin R, Chawla S, Ewer M, et al. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: An update. Invest New Drugs 1985; 3: 117-21.
218. Vile G, Winterbourn C. Microsomal liquid peroxidation induced by Adriamycin, epirubicin, daunorubicin and mitoxantrone: A comparative study. Cancer Chemother Pharmacol 1989; 24: 105-8.
219. Ognibene FP, Rosenberg SA, Lotze M, et al. Interleukin 2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 1989; 94: 750-4.
220. Iguchi H, Tone H, Ischikur T, et al. Pharmacokinetics and disposition of 4′-O-tetrahydropyranyladriamycin in mice by HPLC analysis. Cancer Chemother Pharmacol 1985; 15: 132-40.
221. Mitrou PS, Kuse R, Anger H, et al. Aclarubicin (Aclacinomycin A) in the treatment of relapsing acute leukemia. Eur J Cancer Clin Oncol 1985; 21: 919-23.
222. Kagawa D, Nakamura T, Ueda T, Domae N, Uchino H. Evaluation of oral Aclarubicin treatment for tumours of the gastrointestinal tract. Anticancer Res 1993; 13: 909-14.
223. Trehu EG, Isner JM, Mier JW, Karp DD, et al. Possible myocardial toxicity associated with interleukin 4 therapy. J Immunother 1993; 14: 348-51.
224. Creighton A, Hellman K, Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature 1969; 222: 384-5.
225. Hasinoff B, Kuschak T, Yalowich J, et al. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (detxazoxance). Biochem Pharmacol 1995; 50: 953-8.
226. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-27.
227. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin induced cardiac toxicity in women with advance breast cancer. N Engl J Med 1988; 319: 745-52.
228. Kruit WH, Punt KJ, Goey Sh, de Mulder PH, et al. Cardiotoxicity as a dose limiting factor in a schedule of high dose bolus therapy with interleukin2 and alpha interferon: an unexpectedly frequent complication. Cancer 1994; 74: 2854-6.
229. Arbuck SG, Adams J, Strauss H, et al. A reassessment of cardiac toxicity associated with Taxol (Abstract). Second National Cancer Institute Workshop on Taxol and Taxus, September 23-24, 1992 Alexander Va.
230. Gianni L, Myers C. The role of free radical formation in the cardiotoxicity of anthracycline, in Muggia F, Green M, Speyer J (eds). Cancer Treatment and the Heart. Baltimore MD, Johns Hopkins University 1992: 6-64.
231. Massida B, et al. Early detection of anthracycline induced cardiotoxicity. Anticancer Res 1997; 17: 663-8.
232. Hasinoff BB. The interaction of the cardio protective agent ICRF-187; its hydrolysis product (ICRF-198) and other chelating agent with Fe and Cu Ion complexes of adriamycin. Agents and Actions 1989; 26: 78-385.
233. Ferrans V, Sanctiez J, Herman E. Pathologic anatomy of annual models of the cardiotoxicity of anthracycline. In: Muggia F, Green M, Speyer J (eds). Cancer Treatment and the Heart. Baltimore MD, Johns Hopkins University 1992: 114-69.
234. Hermans E, Ferrans V, Sanchez J. Method of reducing the cardiotoxicity of anthracyclines. In: Muggia F, Green M, Speyer J (eds). Cancer Treatment and the Heart. Baltimore MD, Johns Hopkins University, 1992: 114-69.
235. Speyer J, Green M, Kramer E, et al. Protective effect of the bispiperazine ICRF-187 against doxorubicin induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745-52.
236. Herman EH, Ferrans VJ, Yong RSK, et al. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res 1988; 48: 6918-25.
237. Bulock FA, Gabriel HM, Oakhill A, et al. Cardioprotection by ICRF-187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 1993; 70: 185-8.
238. Verhoef V, Bell B, Filppi J. Effect of the cardioprotective agent ADR529 (ICRF-187) on the antitumor activity of doxorubicin. Proc Am Assoc Cancer Res 1988; 29: 273 (abstract).
239. Herman E, Ferrans V, Sanchez J. Methods of reducing the cardiotoxicity of anthracycline. In: Muggia F, Green M, Speyer J (eds). Cancer Treatment and the Heart. Baltimore, MD, Johns Hopkins University 1992: 114-69.
240. Alderton P, Gross J, Green M. Comparative study of doxorubicin, mitoxantrone and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 1992; 52: 194-201.
241. Speyer J, Green M, Kramer A, Rey M, et al. Protective effect of the bispiperazine ICRF 187 against doxorubicin induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745-52.
242. Maillaird J, Speyer J, Hanson K, Weisberg SR, et al. Prevention of chronic adriamycin cardiotoxicity with the bisdioxopiperazine dexrazoxane (ICRF-187, ADR 529) in patients with advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 1992; 11: 91.
243. Rosenfeld C, Weisberg S, York R, Jones S, et al. Prevention of adriamycin cardiomyopathy with dexrazoxane (abstract). Proc Am Soc Clin Oncol 1992; 62.
244. Weisberg S, Rosenfeld C, York R, Jones C, et al. Dexrazoxane protects against doxorubicin induced chronic cardiotoxicity (abstract). Proc Am Clin Oncol 1992; 11: 91.
245. Sei fert CF, Nesser ME, Thomson DF. Dexrazoxane in the prevention of doxorubicin induced cardiotoxicity. Ann Pharmacol Ther 1994; 28: 1063-72.
246. Donehower RC, Rowinsky EK. An overview of experience with Taxol (paclitaxel) in the USA. Cancer Treat Rev 1993; 19(suppl C): 63-78.
247. Herman EH, Ferrans VJ, Young RS, et al. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res 1988; 48: 6918-25.
248. Herman EH, Ferrans VJ. Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds. Cancer Treat Rev 1987; 14: 225-9.
249. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumour agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991; 51: 4903-8.
250. Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977; 17: 163-7.
251. Hasinoff BB. An HPLC and spectrometric study of the hydrolysis of ICRF-187 and its open ring hydrolysis intermediates. Int J Pharm 1994; 107: 67-76.
252. Hasinoff BB, Reinders FX, Clark V. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent ( + )-1,2-bis(3,5-dioxopiperazinyl-1yl)propane. Drug Metab Disposit 1990; 19: 74-80.
253. Voest E, Van Acker SABE, Van Der Vijgh WJF, et al. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 1994; 26: 1179-85.
254. Brock JH, Halliday JW, Pippard MJ, Powell LW. Iron Metabolism in Health and Disease. WB Saunders Company Ltd, Philadelphia 1994: 353-89.
255. Weiss G, Watcher H, Fuchs D. Linkage of cellular immunity to iron metabolism. Immunol Today 1995; 16: 495-500.
256. Weiss G, Warmer Felmayer G, Warner ER, et al. Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med 1994; 180: 969-76.
257. Sorensen B, Bastholt L, Mirza M, Gjedde S, et al. The cardiac protector ADR-529 and high dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase 1 study in metastatic breast cancer. Cancer Chemother Pharmacol 1994; 34: 439-43.
258. Rogers BB. Taxol: a promising new drug of the 90s. Oncol Nurs Forum 1993; 20(10): 483-9.
259. Spencer CM, Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48: 794-847.
260. Swain S, Whaley F, Gerber M, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin containing therapy. J Clin Oncol 1997; 15: 1333-40.
261. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere: five day schedule. J Natl Cancer Inst 1992; 84: 1781-8.
262. Wexler L, Berg S, Andrich M, Chen C, et al. ICRF-187 reduces doxorubicin induced cardiotoxicity with no impact on response to chemotherapy. Proc Am Soc Clin Oncol 1993; 12: 418.
263. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995; 91: 10-15.
264. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993; 19: 351-86.
265. Klugmann FB, Decorti G, Candussio L. Amelioration of 4 epidoxorubicin induced cardiotoxicity by sodium cromoglycate. Eur J Cancer Clin Oncol 1989; 25: 361-8.
266. DeJong J, Schoofs PR, Onderwater RC, et al. Isolated mouse atrium as a model to study anthracycline cardiotoxicity: the role of the beta-adrenoceptor system and reactive oxygen species. Res Commun Pathol Pharmacol 1990; 68: 275-89.
267. Burris HA, Irvin R, Kuhn J, et al. Phase I clinical trial of Taxotere given as either a 2-hour or a 6-hour infusion. J Clin Oncol 1993; 11: 950-8.
268. Valls V, Castelluccio C, Fato R, et al. Protective effect of exogenous coenzyme Q against damage by adriamycin in perfused rat liver. Biochem Mol Biol Int 1994; 33(4): 633-42.
269. Kishi T, Folkers K. Prevention by coenzyme Q10 (NSC-140865) of the inhibition by adriamycin (NSC-123127) of Coenzyme Q10 enzymes. Cancer Treat Rep 1976; 60(3): 223-4.
270. Clinical Product Monograph on Taxotere. Rhône-Poulenc-Rorer Pharmaceuticals Incorporated 1988; 5/98: 21-7.
271. Anand AJ. Fluorouracil cardioxicity. Ann Pharmacother 1994; 28: 374-8.
272. Labianca R, Beretta G, Clerici M, et al. Cardiotoxicity of 5-FU a study of 1083 patients. Tumori 1982; 68: 505-10.
273. Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high dose 5 fluorouracil infusion: a prospective study. Oncology 1993; 50: 441-4.
274. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5 fluorouracil. J Clin Pharmacol 1993; 33: 10620-70.
275. Gianni L, Straneo M, Capril G, et al. Optimal dose and sequence finding study of paclitaxel by 3 h infusion combined with bolus doxorubicin in untreated metastatic breast cancer patients. Proc Am Soc Clin Oncol 1994; 13: 74.
276. Forni MD, Malet-Martino M, Jaillais P, Shubinski R, et al. Cardiotoxicity of high dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795-801.
277. Ensley J, Kish J, Tapazoglou E, Patel B, et al. 5-fluorouracil infusions associated with an ischaemic cardiotoxicity syndrome. Proc Am Soc Clin Oncol 1986; 5: 142.
278. Lemaire L, Matet-Martino MC, Lorgo S, et al. Fluoro-acetaldehyde as cardiotoxic impurity in Fluorouracil (Roche). Lancet 1991; 337: 560.
279. Nakashima L. A review of taxol: highlights on antineoplastic drugs (Monograph) Princeton, NJ, Bristol-Myers Squibb, 1992.
280. Pottage A, Holt S, Ludgate S, et al. Fluorouracil cardiotoxicity. BMJ 1978; 1: 547.
281. Ensley J, Patel B, Kloner RA, et al. Clinical syndrome of 5-fluorouracil cardiotoxicity. Invest New Drugs 1989; 7: 101-9.
282. Praga C, Beretta G, Labianca R. Cardiac toxicity from antitumor therapy. Oncology 1980; 37(1): 51-8.
283. Chang AY, Kim K, Glick J, et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 5: 388-94.
284. Roth BJ, Yeap BY, Wilding G, et al. Taxol in advanced, hormone-refractory carcinoma of the prostate: a phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993; 72: 2457-60.
285. Patel B, Kloner RA, Ensley J, et al. 5-Fluorouracil cardiotoxicity: Left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987; 294: 238-43.
286. Baker WP, Dainer P, Lester WM, et al. Ischaemic chest pain after 5-fluorouracil therapy for cancer. Am J Cardiol 1986; 57: 497-8.
287. deForni M, Malet-Martino MC, Jailais P, et al. Cardiotoxicity of high dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795-801.
288. Freeman NJ, Costanza ME. 5-Fluorouracil associated cardiotoxicity. Cancer 1988; 61: 36-45.
289. McKendall GR, Shurman A, Anamur M, et al. Toxic cardiogenic shock associated with infusion of 5-fluorouracil. Am Heart J 1989; 118: 184-6.
290. Riella AR, Kimball JC, Patterson RB. 5-FU cardiotoxicity. Cancer Treat Rep 1981; 65: 1123-5.
291. Burger AJ, Mannino S. 5-Fluorouracil induced coronary vasospasm. Am Heart J 1987; 114:433-6.
292. Collins C, Weiden PL. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 1987; 71: 733-6.
293. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. Cancer 1992; 71(2): 493-509.
294. Haskel CM. Drugs used in cancer chemotherapy. In: Haskel CM, et al. (eds). Cancer Treatment. 2nd ed. Philadelphia: WB Saunders, 1984; 43-106.
295. Chaudari S, Song SYT, Jaski BE. Profound yet reversible heart failure secondary 5-fluorouracil. Am J Med 1988; 85: 454-6.
296. Bristol-Myers Squibb. Taxol administration guide. Princeton, NJ: Bristol-Myers Squibb 1993.
297. Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity: the role of Krebs cycle inhibition by fluoroacetate. Arch Neural 1970; 23: 155-60.
298. Walker FE. Paclitaxel (Taxol): side effects and patient education issues. Semin Oncol Nurs 1993; 9(4 suppl 2): 6-10.
299. Lemaire L, Arellano M, Malet-Martino MC, Martino R, De Forni M. Cardiotoxicité du 5-Fluorouracile: une question de formulation. Bull Cancer 1994; 81: 1057-9.
300. Rovinsky EK, McGuire WP, Guarneiri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9: 1704-12.
301. Lemaire L, Malet-Martino MC, deForni M, et al. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer 1992; 66: 119-27.
302. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of taxotore (RP 56976: NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53: 1037-42.
303. Stevenson DL, Mikhailidis DP, Gillett DS, et al. Cardiotoxicity of 5 fluorouracil. Lancet 1977; 2: 406-7.
304. LH Wexler, MP Andrich, D Venzon, et al. Randomised trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14(2): 362-72.
305. Green MD, Alderton P, Gross J, et al. Evidence of the selective alteration of the anthracycline activity due to modulation by ICRF-187 (ADR-529). Pharmacol Ther 1990; 48: 61-9.
306. Kleiman NS, Lehane DE, Geyer CE, et al. Prinzmetal's angina during 5-Fluorouracil chemotherapy. Am J Med 1987; 82: 566-8.
307. Gottdiener JS, Applebaum F, Ferrans V, Deisseroth A, et al. Cardiac toxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-63.
308. Cazin B, Gorin NC, Laporte JP, Gallet B, Douay L, Lopez M, Najman A, Duhamel P. Cardiac complications after bone marrow transplantation: a report on a series of 63 consecutive patients. Cancer 1986; 57: 2061-9.
309. Wadler S, Green MD, Muggia FM. Synergistic activity of doxorubicin and the bisdioxopiperazine( + ) 12-bis(3-5-dioxopiperazinyl-1-yl) propane (ICRF-187) against the murinesarcoma S 180 cell line. Cancer Res 1986; 46: 1176-81.
310. Buja LM, Ferrans VJ, Graw, RG. Cardiac pathologic findings in patients treated with bone marrow transplantation. Hum Pathol 1976; 7: 17-45.
311. Frishman WH, Sung HM, Yee HC, Liu LL, et al. Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cancer 1997 Nov-Dec; 21(6): 301-60.
312. Wadler S, Green MD, Busch R, et al. Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine( + ) 12-bis(3-5-dioxopiperazinyl-1-yl) propane (ICRF-187) against the murinesarcoma S 180 in vitro. Biochem Pharmacol 1987; 36: 1495-501.
313. Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphate Cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9: 1215-23.
314. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-63.
315. Kupari M, Volin L, Suokas A, Timonen T, Hekali P, Ruutu T. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 1990; 5: 91-8.
316. Steinherz LJ, Steinherz PG, et al. Cardiac changes with cyclophosphamide. Med Ped Oncol 1981; 9: 417-22.
317. Appelbaum, FR, Strauchen, JA and Graw JR, et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1976; 1: 58-62.
318. Donehower RC, Rowinsky EK. An overview of experience with Taxol (paclitaxel) in the USA. Cancer Treat Rev 1993; 19(suppl C): 63-78.
319. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advance ovarian epithelial neoplasms. Ann Itern Med 1989; 111: 273-9.
320. Slavin RE, Millan JC, Mullins GM. Pathology of high-dose intermittent cyclophosphamide therapy. Human Pathol 1975; 6: 693-709.
321. Manthorpe R, Svensson O. Cyclophosphamide induced cardiomyopathy in a patient with life threatening ANCA positive Wegener's granulomatosis. J Int Med 1990; 228 suppl 773: 42.
322. Sculier JP, Coune A, Klastersky J. Transient heart block, an unreported toxicity of high dose chemotherapy with cyclophosphamide and etoposide. Acta Clin Belg 1985; 40: 112-14.
323. Shachor J, Beker B, et al. Acute ECG changes during cyclophosphamide infusion in a patient with bronchogenic carcinoma. Cancer Treat Rep 1985; 69: 734-5.
324. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose vs low-dose and long vs short infusion. J Clin Oncol 1994; 12: 2654-66.
325. Dimitriadis K, Stergiou I, et al. Cardiotoxicity of Ifosfamide. Preliminary results of a prospective study. Intern Cancer Congress, Hamburg 1990; 15.
326. Elias AD, Eder JP, et al. High-dose Ifosfamide with Mesna Uroprotection: A phase I study. J Clin Oncol 1990; 8: 170-8.
327. Klein HO, Wickramanayake P, et al. Therapeutic effects of single push or fractionated injections of cyclophosphamide or ifosfamide combined with Mesna. Cancer Treat Rev 1983; 10 suppl A: 83-92.
328. Kandylis K, Vassilomanolakis M, et al. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 1989; 24: 395-6.
329. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692-703.
330. Ramreddy K, Lare KM, Adhor G. Acquired heart block after high dose chemotherapy with cyclophosphamide and thiotepa. Am Heart J 1994; 127: 701-4.
331. Kenyon J (ed). Paclitaxel: a promising addition to the antineoplastic armamentarium. Drugs Therapy Perspective Rational Drug Selection Use 1995; 5(3): 1-5.
332. Airbuck S, Strauss H, Christian M, et al. A reassessment of cardiac toxicity associated with taxol. Proc Am Soc Clin Oncol 1993; 12: 138.
333. Gibbs H, Ewer M, Holmes F, et al. Cardiac monitoring during administration of taxel-doxorubicin chemotherapy in patients with metastatic breast cancer; A preliminary report. Proc Am Soc Clin Oncol 1993; 12: 138.
334. Verweij J, Clavel M, Chevallier B: Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. Ann Oncol 1994; 5: 495-505.
335. Lubejiko BG, Sartorius SE. Nursing considerations in Paclitaxel (TAXOL) administration. Semin Oncol 1993; 20(suppl 3): 26-30.
336. Sparreboom A, Huizing MT, Boesen JJ, Noojen WJ, van Tellingen O, Beijnen JH. Isolation, purification and biological activity of mono and dihydroxylated Paclitaxel metabolites from human feces. Cancer Chemother Pharmacol 1995; 36: 299-304.
337. Bissery MC, Guenard D, Gueritte-Voegelein F, et al. Experimental antitumor activity of Taxotere (RP 56976,NSC628503) a Taxol analogue. Cancer Res 1991; 51: 4845-52.
338. Runowicz CD, Wiernik PH, Einzig AI, Goldberg GL, Horwitz SB. Taxol in ovarian cancer. Cancer 1993; 71: 1591-6.
339. Valdes RA, TenBokel-Huinink WW, Greve JC, et al. I-123 MIBG and serial radionuclide angiography in doxorubicin related cardiotoxicity. Clin Nucl Med 1992; 17: 163-7.
340. Nitsu N, Yamazaki J, Igarashi M, et al. Clinical usefulness of 123-I MIBG myocardial SPECT in patients with adriamycin induced cardiomyopathy. Jpn J Nucl Med 1994; 31: 1051-7